Abstract:Acute promyelocytic leukemia (APL) is a type of acute leukemia, which has the highest death rate among blood cancers and caused by a specific (15; 17) chromosomal translocation, resulting in a fusion gene PML/RARα. Klotho gene plays a role in preventing aging, inflammation and cancer. CTLA4, PD1 and LAG3 are immunosuppressive receptors located on surface of T cells and considered as a negative regulation of immune response. These genes regulate immune cell activity through several signalling moleculars such as STATs and NF-κB. In this study, to additionally determine the difference between APL and other leukemia, we performed experiments to measure mRNA expression of above genes by using realtime-PCR. Results showed that mRNA levels of KL, CTLA4, PD1 and LAG3 genes were lower, while expressions of STAT1, STAT3, STAT5 and STAT6 genes were significantly higher in APL patients than healthy controls. In addition, IκB-α gene expression was unaltered on APL cells. The results of this study would partially contribute to an understanding of the differences in JAK-STAT signaling associated gene expressions between APL and other leukemia groups. This is important to apply for effective chemotherapy for each type of leukemia. Keywords Acute promyelocytic leukemia, klotho, CTLA4, IκB-α, LAG3, PD1, STAT. References [1] M. Gianni, M. Terao, I. Fortino, M. LiCalzi, V. Viggiano, T. Barbui, A. Rambaldi, E. Garattini, Stat1 is induced and activated by all-trans retinoic acid in acute promyelocytic leukemia cells, Blood, 89 (1997) 1001-1012.[2] A. Kohlmann, C. Schoch, M. Dugas, S. Rauhut, F. Weninger, S. Schnittger, W. Kern, T. Haferlach, Pattern robustness of diagnostic gene expression signatures in leukemia, Genes, chromosomes & cancer, 42 (2005) 299-307.[3] C.B. Leibrock, J. Voelkl, O.M. Kuro, F. Lang, U.E. Lang, 1,25(OH)2D3 dependent overt hyperactivity phenotype in klotho-hypomorphic mice, Scientific reports, 6 (2016) 24879.[4] D. Skrajnowska, B. Bobrowska-Korczak, A. Tokarz, Disorders of Mechanisms of Calcium Metabolism Control as Potential Risk Factors of Prostate Cancer, Current medicinal chemistry, 24 (2017) 4229-4244.[5] V. Delcroix, O. Mauduit, N. Tessier, A. Montillaud, T. Lesluyes, T. Ducret, F. Chibon, F. Van Coppenolle, S. Ducreux, The Role of the Anti-Aging Protein Klotho in IGF-1 Signaling and Reticular Calcium Leak: Impact on the Chemosensitivity of Dedifferentiated Liposarcomas, 10 (2018).[6] M. Azuma, D. Koyama, J. Kikuchi, H. Yoshizawa, D. Thasinas, K. Shiizaki, M. Kuro-o, Y. Furukawa, E. Kusano, Promoter methylation confers kidney-specific expression of the Klotho gene, FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 26 (2012) 4264-4274.[7] E.L. Masteller, E. Chuang, A.C. Mullen, S.L. Reiner, C.B. Thompson, Structural analysis of CTLA-4 function in vivo, Journal of immunology (Baltimore, Md. : 1950), 164 (2000) 5319-5327.[8] B.T. Fife, J.A. Bluestone, Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways, Immunological reviews, 224 (2008) 166-182.[9] L.P. Andrews, A.E. Marciscano, C.G. Drake, D.A. Vignali, LAG3 (CD223) as a cancer immunotherapy target, Immunological reviews, 276 (2017) 80-96.[10] B. Huard, P. Prigent, M. Tournier, D. Bruniquel, F. Triebel, CD4/major histocompatibility complex class II interaction analyzed with CD4- and lymphocyte activation gene-3 (LAG-3)-Ig fusion proteins, European journal of immunology, 25 (1995) 2718-2721.[11] F. Xu, J. Liu, D. Liu, B. Liu, M. Wang, Z. Hu, X. Du, L. Tang, F. He, LSECtin expressed on melanoma cells promotes tumor progression by inhibiting antitumor T-cell responses, Cancer research, 74 (2014) 3418-3428.[12] J. Kotaskova, B. Tichy, M. Trbusek, H.S. Francova, J. Kabathova, J. Malcikova, M. Doubek, Y. Brychtova, J. Mayer, S. Pospisilova, High expression of lymphocyte-activation gene 3 (LAG3) in chronic lymphocytic leukemia cells is associated with unmutated immunoglobulin variable heavy chain region (IGHV) gene and reduced treatment-free survival, The Journal of molecular diagnostics: JMD, 12 (2010) 328-334.[13] P. Aigner, T. Mizutani, J. Horvath, T. Eder, STAT3beta is a tumor suppressor in acute myeloid leukemia, 3 (2019) 1989-2002.[14] C. Schubert, M. Allhoff, S. Tillmann, T. Maie, I.G. Costa, D.B. Lipka, M. Schemionek, K. Feldberg, J. Baumeister, T.H. Brummendorf, N. Chatain, S. Koschmieder, Differential roles of STAT1 and STAT2 in the sensitivity of JAK2V617F- vs. BCR-ABL-positive cells to interferon alpha, Journal of hematology & oncology, 12 (2019) 36.[15] T. Bowman, R. Garcia, J. Turkson, R. Jove, STATs in oncogenesis, Oncogene, 19 (2000) 2474-2488.[16] C. Gasparini, C. Celeghini, L. Monasta, G. Zauli, NF-kappaB pathways in hematological malignancies, Cellular and molecular life sciences : CMLS, 71 (2014) 2083-2102.[17] S. Prasad, J. Ravindran, B.B. Aggarwal, NF-kappaB and cancer: how intimate is this relationship, Molecular and cellular biochemistry, 336 (2010) 25-37.[18] N. Erfani, S.M. Mehrabadi, M.A. Ghayumi, M.R. Haghshenas, Z. Mojtahedi, A. Ghaderi, D. Amani, Increase of regulatory T cells in metastatic stage and CTLA-4 over expression in lymphocytes of patients with non-small cell lung cancer (NSCLC), Lung cancer (Amsterdam, Netherlands), 77 (2012) 306-311.[19] K.V. Shah, A.J. Chien, C. Yee, R.T. Moon, CTLA-4 is a direct target of Wnt/beta-catenin signaling and is expressed in human melanoma tumors, The Journal of investigative dermatology, 128 (2008) 2870-2879.[20] S. Salvi, V. Fontana, S. Boccardo, D.F. Merlo, E. Margallo, S. Laurent, A. Morabito, E. Rijavec, M.G. Dal Bello, M. Mora, G.B. Ratto, F. Grossi, M. Truini, M.P. Pistillo, Evaluation of CTLA-4 expression and relevance as a novel prognostic factor in patients with non-small cell lung cancer, Cancer immunology, immunotherapy : CII, 61 (2012) 1463-1472.[21] M. Grzywnowicz, J. Zaleska, D. Mertens, W. Tomczak, P. Wlasiuk, K. Kosior, A. Piechnik, A. Bojarska-Junak, A. Dmoszynska, K. Giannopoulos, Programmed death-1 and its ligand are novel immunotolerant molecules expressed on leukemic B cells in chronic lymphocytic leukemia, PloS one, 7 (2012) e35178.[22] L. Long, X. Zhang, F. Chen, Q. Pan, P. Phiphatwatchara, Y. Zeng, H. Chen, The promising immune checkpoint LAG-3: from tumor microenvironment to cancer immunotherapy, Genes & cancer, 9 (2018) 176-189.[23] R.R. Saleh, P. Peinado, J. Fuentes-Antras, P. Perez-Segura, A. Pandiella, E. Amir, A. Ocana, Prognostic Value of Lymphocyte-Activation Gene 3 (LAG3) in Cancer: A Meta-Analysis, Frontiers in oncology, 9 (2019) 1040.[24] H.A. Jensen, H.B. Yourish, R.P. Bunaciu, J.D. Varner, A. Yen, Induced myelomonocytic differentiation in leukemia cells is accompanied by noncanonical transcription factor expression, FEBS open bio, 5 (2015) 789-800.[25] B. Kovacic, D. Stoiber, R. Moriggl, E. Weisz, R.G. Ott, R. Kreibich, D.E. Levy, H. Beug, M. Freissmuth, V. Sexl, STAT1 acts as a tumor promoter for leukemia development, Cancer cell, 10 (2006) 77-87.[26] V. Gouilleux-Gruart, F. Gouilleux, C. Desaint, J.F. Claisse, J.C. Capiod, J. Delobel, R. Weber-Nordt, I. Dusanter-Fourt, F. Dreyfus, B. Groner, L. Prin, STAT-related transcription factors are constitutively activated in peripheral blood cells from acute leukemia patients, Blood, 87 (1996) 1692-1697.[27] R.M. Weber-Nordt, C. Egen, J. Wehinger, W. Ludwig, V. Gouilleux-Gruart, R. Mertelsmann, J. Finke, Constitutive activation of STAT proteins in primary lymphoid and myeloid leukemia cells and in Epstein-Barr virus (EBV)-related lymphoma cell lines, Blood, 88 (1996) 809-816.[28] H.A. Bruns, M.H. Kaplan, The role of constitutively active Stat6 in leukemia and lymphoma, Critical reviews in oncology/hematology, 57 (2006) 245-253.[29] B.H. Li, X.Z. Yang, P.D. Li, Q. Yuan, X.H. Liu, J. Yuan, W.J. Zhang, IL-4/Stat6 activities correlate with apoptosis and metastasis in colon cancer cells, Biochemical and biophysical research communications, 369 (2008) 554-560.[30] N. Carlesso, D.A. Frank, J.D. Griffin, Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl, The Journal of experimental medicine, 183 (1996) 811-820.[31] S.K. Chai, G.L. Nichols, P. Rothman, Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients, Journal of immunology (Baltimore, Md.: 1950), 159 (1997) 4720-4728.[32] K. Shuai, J. Halpern, J. ten Hoeve, X. Rao, C.L. Sawyers, Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia, Oncogene, 13 (1996) 247-254.

Abstract:British Journal of HaematologyEarly View LETTER TO THE EDITOR Unveiling myeloid transformation: T-LGLL with eosinophilia masking myeloid-associated STAT5B mutation culminating in AML Qianze Dong, Qianze Dong Department of Pathology, Case Western Reserve University, Cleveland, Ohio, USASearch for more papers by this authorYang Wang, Yang Wang Department of Pathology, Case Western Reserve University, Cleveland, Ohio, USASearch for more papers by this authorYan Xiu, Yan Xiu Department of Pathology, Case Western Reserve University, Cleveland, Ohio, USASearch for more papers by this authorXiaogang Wu, Xiaogang Wu Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USASearch for more papers by this authorStacey O'Neill, Stacey O'Neill Department of Pathology, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USASearch for more papers by this authorHoward Meyerson, Howard Meyerson Department of Pathology, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USASearch for more papers by this authorSuske Tobias, Suske Tobias Institute of Animal Breeding and Genetics, University of Veterinary Medicine, Vienna, AustriaSearch for more papers by this authorRichard Moriggl, Richard Moriggl Institute of Animal Breeding and Genetics, University of Veterinary Medicine, Vienna, AustriaSearch for more papers by this authorShimin Hu, Shimin Hu orcid.org/0000-0001-7110-3814 Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USASearch for more papers by this authorWei Wang, Corresponding Author Wei Wang [email protected] orcid.org/0000-0001-6821-4556 Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA Correspondence Wei Wang, Department of Hematopathology, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA. Email: [email protected] Chen Zhao, Department of Pathology, Case Western Reserve University, Wolstein Research Building, Room 6532, 2103 Cornell Road, Cleveland, OH 44106-7288, USA. Email: [email protected]Search for more papers by this authorChen Zhao, Corresponding Author Chen Zhao [email protected] orcid.org/0000-0003-3217-0269 Department of Pathology, Case Western Reserve University, Cleveland, Ohio, USA Department of Pathology, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA Department of Medicine, Section of Hematology, Louis Stokes Veterans Affairs Medical Center, Cleveland, Ohio, USA Correspondence Wei Wang, Department of Hematopathology, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA. Email: [email protected] Chen Zhao, Department of Pathology, Case Western Reserve University, Wolstein Research Building, Room 6532, 2103 Cornell Road, Cleveland, OH 44106-7288, USA. Email: [email protected]Search for more papers by this author Qianze Dong, Qianze Dong Department of Pathology, Case Western Reserve University, Cleveland, Ohio, USASearch for more papers by this authorYang Wang, Yang Wang Department of Pathology, Case Western Reserve University, Cleveland, Ohio, USASearch for more papers by this authorYan Xiu, Yan Xiu Department of Pathology, Case Western Reserve University, Cleveland, Ohio, USASearch for more papers by this authorXiaogang Wu, Xiaogang Wu Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USASearch for more papers by this authorStacey O'Neill, Stacey O'Neill Department of Pathology, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USASearch for more papers by this authorHoward Meyerson, Howard Meyerson Department of Pathology, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USASearch for more papers by this authorSuske Tobias, Suske Tobias Institute of Animal Breeding and Genetics, University of Veterinary Medicine, Vienna, AustriaSearch for more papers by this authorRichard Moriggl, Richard Moriggl Institute of Animal Breeding and Genetics, University of Veterinary Medicine, Vienna, AustriaSearch for more papers by this authorShimin Hu, Shimin Hu orcid.org/0000-0001-7110-3814 Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USASearch for more papers by this authorWei Wang, Corresponding Author Wei Wang [email protected] orcid.org/0000-0001-6821-4556 Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA Correspondence Wei Wang, Department of Hematopathology, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA. Email: [email protected] Chen Zhao, Department of Pathology, Case Western Reserve University, Wolstein Research Building, Room 6532, 2103 Cornell Road, Cleveland, OH 44106-7288, USA. Email: [email protected]Search for more papers by this authorChen Zhao, Corresponding Author Chen Zhao [email protected] orcid.org/0000-0003-3217-0269 Department of Pathology, Case Western Reserve University, Cleveland, Ohio, USA Department of Pathology, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA Department of Medicine, Section of Hematology, Louis Stokes Veterans Affairs Medical Center, Cleveland, Ohio, USA Correspondence Wei Wang, Department of Hematopathology, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA. Email: [email protected] Chen Zhao, Department of Pathology, Case Western Reserve University, Wolstein Research Building, Room 6532, 2103 Cornell Road, Cleveland, OH 44106-7288, USA. Email: [email protected]Search for more papers by this author First published: 20 March 2024 https://doi.org/10.1111/bjh.19421Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat Supporting Information Filename Description bjh19421-sup-0001-supinfo.docxWord 2007 document , 22.4 KB Data S1. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article. REFERENCES 1Smith MR, Satter LRF, Vargas-Hernandez A. STAT5b: a master regulator of key biological pathways. Front Immunol. 2022; 13:1025373. 10.3389/fimmu.2022.1025373 CASPubMedWeb of Science®Google Scholar 2Kollmann S, Grausenburger R, Klampfl T, Prchal-Murphy M, Bastl K, Pisa H, et al. A STAT5B-CD9 axis determines self-renewal in hematopoietic and leukemic stem cells. Blood. 2021; 138(23): 2347–2359. 10.1182/blood.2021010980 CASPubMedWeb of Science®Google Scholar 3Ariyoshi K, Nosaka T, Yamada K, Onishi M, Oka Y, Miyajima A, et al. Constitutive activation of STAT5 by a point mutation in the SH2 domain. J Biol Chem. 2000; 275(32): 24407–24413. 10.1074/jbc.M909771199 CASPubMedWeb of Science®Google Scholar 4Ma CA, Xi L, Cauff B, DeZure A, Freeman AF, Hambleton S, et al. Somatic STAT5b gain-of-function mutations in early onset nonclonal eosinophilia, urticaria, dermatitis, and diarrhea. Blood. 2017; 129(5): 650–653. 10.1182/blood-2016-09-737817 CASPubMedWeb of Science®Google Scholar 5Pham HTT, Maurer B, Prchal-Murphy M, Grausenburger R, Grundschober E, Javaheri T, et al. STAT5BN642H is a driver mutation for T cell neoplasia. J Clin Invest. 2018; 128(1): 387–401. 10.1172/JCI94509 PubMedWeb of Science®Google Scholar 6Cross NCP, Hoade Y, Tapper WJ, Carreno-Tarragona G, Fanelli T, Jawhar M, et al. Recurrent activating STAT5B N642H mutation in myeloid neoplasms with eosinophilia. Leukemia. 2019; 33(2): 415–425. 10.1038/s41375-018-0342-3 CASPubMedWeb of Science®Google Scholar 7de Araujo ED, Erdogan F, Neubauer HA, Meneksedag-Erol D, Manaswiyoungkul P, Eram MS, et al. Structural and functional consequences of the STAT5B(N642H) driver mutation. Nat Commun. 2019; 10(1): 2517. 10.1038/s41467-019-10422-7 PubMedWeb of Science®Google Scholar 8Rajala HL, Eldfors S, Kuusanmäki H, van Adrichem A, Olson T, Lagström S, et al. Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia. Blood. 2013; 121(22): 4541–4550. 10.1182/blood-2012-12-474577 CASPubMedWeb of Science®Google Scholar 9Andersson EI, Tanahashi T, Sekiguchi N, Gasparini VR, Bortoluzzi S, Kawakami T, et al. High incidence of activating STAT5B mutations in CD4-positive T-cell large granular lymphocyte leukemia. Blood. 2016; 128(20): 2465–2468. 10.1182/blood-2016-06-724856 CASPubMedWeb of Science®Google Scholar 10Kucuk C, Jiang B, Hu X, Zhang W, Chan JKC, Xiao W, et al. Activating mutations of STAT5B and STAT3 in lymphomas derived from gammadelta-T or NK cells. Nat Commun. 2015; 6: 6025. 10.1038/ncomms7025 CASPubMedWeb of Science®Google Scholar 11Kavesh M, Mohebnasab M, Angel MR, Xie W, Raess PW, Cui W, et al. Distinguishing STAT3/STAT5B-mutated large granular lymphocyte leukemia from myeloid neoplasms by genetic profiling. Blood Adv. 2023; 7(1): 40–45. 10.1182/bloodadvances.2022008192 CASPubMedWeb of Science®Google Scholar 12Sreedharanunni S, Jamwal M, Balakrishnan A, Aravindan AV, Sharma R, Singh N, et al. Chronic eosinophilic leukemia with recurrent STAT5B N642H mutation—an entity with features of myelodysplastic syndrome/ myeloproliferative neoplasm overlap. Leuk Res. 2022; 112:106753. 10.1016/j.leukres.2021.106753 CASPubMedWeb of Science®Google Scholar 13Qu S, Jia Y, Wang H, Ai X, Xu Z, Qin T, et al. STAT3 and STAT5B mutations have unique distribution in T-cell large granular lymphocyte proliferations and advanced myeloid neoplasms. Leuk Lymphoma. 2021; 62(6): 1506–1509. 10.1080/10428194.2020.1869964 CASPubMedWeb of Science®Google Scholar 14Lamy T, Moignet A, Loughran TP Jr. LGL leukemia: from pathogenesis to treatment. Blood. 2017; 129(9): 1082–1094. 10.1182/blood-2016-08-692590 CASPubMedWeb of Science®Google Scholar Early ViewOnline Version of Record before inclusion in an issue ReferencesRelatedInformation

High activation of STAT5A drives peripheral T-cell lymphoma and leukemia

Intramolecular hydrophobic interactions are critical mediators

Abstract 5511: Lineage-specific and Shared Cytokine-Sensing Genes Respond Distinctly to the Master Regulator STAT5

STAT5B leukemic mutations, altering SH2 tyrosine 665, have opposing impacts on immune gene programs

STAT1 Gain-of-Function Mutations Cause High Total STAT1 Levels With Normal Dephosphorylation

Activating mutations of STAT5B and STAT3 in lymphomas derived from γδ-T or NK cells

Data from Clinical Implications of Phosphorylated STAT3 Expression in <i>de Novo</i> Diffuse Large B-cell Lymphoma

Stat5-deficient hematopoiesis is permissive for Myc-induced B-cell leukemogenesis

Jak-Stat Signaling Pathway Related Gene Expressions and Blood Biochemical indicators in Acute Promyelocytic Leukemia

Enhanced T Cell Lymphoma in NOD.Stat5b Transgenic Mice is Caused by Hyperactivation of Stat5b in CD8+ Thymocytes

STAT5 antagonism of B cell superenhancer networks initiates progenitor B cell leukemia and predicts patient survival (HEM1P.222)

STAT3 mutations identified in human hematologic neoplasms induce myeloid malignancies in a mouse bone marrow transplantation model

Activating mutations of STAT 5 B and STAT 3 in lymphomas derived from gdT or NK cells

Identification of Pstat5 Gene Signature in Hematologic Malignancy

Frequent Activating Mutations of JAK-STAT Pathway Genes in Natural Killer Cell Lymphomas

Unveiling Myeloid Transformation: T‐LGLL with Eosinophilia Masking Myeloid‐associated STAT5B Mutation Culminating in AML

STAT5 is essential for inducing the suppressive subset and attenuate cytotoxicity of Vδ2 + T cells in acute myeloid leukemia

A lineage-specific STAT5BN642H mouse model to study NK-cell leukemia

Constitutive activation of STAT transcription factors in acute myelogenous leukemia

Implications of STAT3 and STAT5 signaling on gene regulation and chromatin remodeling in hematopoietic cancer

STAT5B mutations in myeloid neoplasms differ by disease subtypes but characterize a subset of chronic myeloid neoplasms with eosinophilia and/or basophilia